Ezetimibe - A clinically effective and a cost-effective treatment option for dyslipidaemia
Although statins are first-line treatment for most patients with dyslipidaemia, some people require additional or alternative treatment to modify their lipid profile. Many patients treated with statins still fail to achieve increasingly stringent LDL-C goals in clinical practice, and can benefit fro...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2008
|
| _version_ | 1826267472309780480 |
|---|---|
| author | Croom, K Kassianos, G Gaw, A Kirby, M Morrell, J Schachler, M Tamargo, J Yawn, B Yawn, R Barakal, K Brown, P Dalrymple, J Elward, K Ganiats, T Halpin, D LeFevre, M North, F Price, D Rasmussen, F Spann, S Stevens, R Tallia, A Uden, D Waile, M Waller, D |
| author_facet | Croom, K Kassianos, G Gaw, A Kirby, M Morrell, J Schachler, M Tamargo, J Yawn, B Yawn, R Barakal, K Brown, P Dalrymple, J Elward, K Ganiats, T Halpin, D LeFevre, M North, F Price, D Rasmussen, F Spann, S Stevens, R Tallia, A Uden, D Waile, M Waller, D |
| author_sort | Croom, K |
| collection | OXFORD |
| description | Although statins are first-line treatment for most patients with dyslipidaemia, some people require additional or alternative treatment to modify their lipid profile. Many patients treated with statins still fail to achieve increasingly stringent LDL-C goals in clinical practice, and can benefit from add-on ezetimibe therapy, which has a complementary mechanism of action to other drugs in current use. Many clinical studies have demonstrated that combinations of ezetimibe with statins, fibrates, and other lipid-modifying therapies, provide better normalisation of lipid profiles than these drugs given as monotherapy. Moreover, ezetimibe is also effective as a monotherapy. The safety and tolerability profile of ezetimibe as monotherapy is similar to placebo, and is also excellent when given in combination with other lipid-modifying agents. Ezetimibe may also provide a cost-effective alternative to statin titration. These findings suggest that ezetimibe represents a useful alternative and adjunct to other lipid management strategies. © 2008 CSF Medical Communications Ltd. |
| first_indexed | 2024-03-06T20:54:43Z |
| format | Journal article |
| id | oxford-uuid:38cab30f-4e74-420f-8e8a-e7b62347a4e3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:54:43Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | oxford-uuid:38cab30f-4e74-420f-8e8a-e7b62347a4e32022-03-26T13:52:14ZEzetimibe - A clinically effective and a cost-effective treatment option for dyslipidaemiaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:38cab30f-4e74-420f-8e8a-e7b62347a4e3EnglishSymplectic Elements at Oxford2008Croom, KKassianos, GGaw, AKirby, MMorrell, JSchachler, MTamargo, JYawn, BYawn, RBarakal, KBrown, PDalrymple, JElward, KGaniats, THalpin, DLeFevre, MNorth, FPrice, DRasmussen, FSpann, SStevens, RTallia, AUden, DWaile, MWaller, DAlthough statins are first-line treatment for most patients with dyslipidaemia, some people require additional or alternative treatment to modify their lipid profile. Many patients treated with statins still fail to achieve increasingly stringent LDL-C goals in clinical practice, and can benefit from add-on ezetimibe therapy, which has a complementary mechanism of action to other drugs in current use. Many clinical studies have demonstrated that combinations of ezetimibe with statins, fibrates, and other lipid-modifying therapies, provide better normalisation of lipid profiles than these drugs given as monotherapy. Moreover, ezetimibe is also effective as a monotherapy. The safety and tolerability profile of ezetimibe as monotherapy is similar to placebo, and is also excellent when given in combination with other lipid-modifying agents. Ezetimibe may also provide a cost-effective alternative to statin titration. These findings suggest that ezetimibe represents a useful alternative and adjunct to other lipid management strategies. © 2008 CSF Medical Communications Ltd. |
| spellingShingle | Croom, K Kassianos, G Gaw, A Kirby, M Morrell, J Schachler, M Tamargo, J Yawn, B Yawn, R Barakal, K Brown, P Dalrymple, J Elward, K Ganiats, T Halpin, D LeFevre, M North, F Price, D Rasmussen, F Spann, S Stevens, R Tallia, A Uden, D Waile, M Waller, D Ezetimibe - A clinically effective and a cost-effective treatment option for dyslipidaemia |
| title | Ezetimibe - A clinically effective and a cost-effective treatment option for dyslipidaemia |
| title_full | Ezetimibe - A clinically effective and a cost-effective treatment option for dyslipidaemia |
| title_fullStr | Ezetimibe - A clinically effective and a cost-effective treatment option for dyslipidaemia |
| title_full_unstemmed | Ezetimibe - A clinically effective and a cost-effective treatment option for dyslipidaemia |
| title_short | Ezetimibe - A clinically effective and a cost-effective treatment option for dyslipidaemia |
| title_sort | ezetimibe a clinically effective and a cost effective treatment option for dyslipidaemia |
| work_keys_str_mv | AT croomk ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT kassianosg ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT gawa ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT kirbym ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT morrellj ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT schachlerm ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT tamargoj ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT yawnb ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT yawnr ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT barakalk ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT brownp ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT dalrymplej ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT elwardk ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT ganiatst ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT halpind ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT lefevrem ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT northf ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT priced ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT rasmussenf ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT spanns ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT stevensr ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT talliaa ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT udend ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT wailem ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia AT wallerd ezetimibeaclinicallyeffectiveandacosteffectivetreatmentoptionfordyslipidaemia |